VYVanessa Yang

Vanessa Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vanessa Yang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

  • Open Access

    Supplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)

  • Open Access

    Supplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences in murine serum GAS6 levels among groups detected by ELISA

  • Open Access

    Supplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls in intratibial LuCaP 147CR PDX model while total AKT proteins levels were similar. Scale bar = 10 μm.

  • Open Access

    Supplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibiae of LuCaP 147 (A), and LuCaP 35 (B). Human PCa cells marked by Ku70 were significantly decreased after 30 days of treatment by intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, docetaxel (10 mg/kg/QW, n = 9) or the combination of batiraxcept (20 mg/kg/QOD, n = 9) and docetaxel (10 mg/kg/QW, n = 9) compared to vehicle controls (n = 8,10). C-D, Quantification of the IHC Ku70-positive areas in mouse tibia specimens treated with vehicle, batiraxcept, docetaxel, and batiraxcept + docetaxel in A-B. Fold change: combination batiraxcept and docetaxel (B+D) group set as 1. E, Inhibition of LuCaP 147CR tumor cells metastasis to mouse lung lobes by batiraxcept, docetaxel, and batiraxcept + docetaxel combination therapy. The arrowheads indicate Ku70-positive metastatic tumor nodules in the lung, which metastasized from the mice tibiae. F, Quantification of fold changes (docetaxel group set as 1) of human-specific GAPDH level normalized against universal GAPDH level in different treatment groups for LuCaP 147CR. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 0.05 not significant. All scale bar = 50 μm.

  • Open Access

    Data from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Purpose:After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental Design:Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes.Results:High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways.Conclusions:Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.

  • Open Access

    Supplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse serum PSA detected by ELISA.

  • Open Access

    Supplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination increased bone mineral density (BMD) of the tibiae to a similar extent as determined by microCT.

  • Open Access

    Supplementary Figure S5 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Figure S5. Mouse body weight change (%) after treatment for 30 days. None of the treatment groups displayed significant differences in body weight, indicating overall low toxicity from batiraxcept and docetaxel at the doses administered.

  • Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

    by Chun-Lung Chiu, Dalin Zhang, Hongjuan Zhao, Yi Wei, Alexandra Lapat Polasko, Mikkel Thy Thomsen, Vanessa Yang, Kasie Kexin Yang, Spencer Hauck, Eric E. Peterson, et al.

    Purpose: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed. Experimental Design: Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes. Results: High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways. Conclusions: Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.